New $2.9 Million Gene Therapy Promises to Remake Hemophilia Treatment
Wall Street Journal
BioMarin’s gene therapy is the first to win Food and Drug Administration approval for adults with the most common form of the bleeding disorder.
Wall Street Journal
BioMarin’s gene therapy is the first to win Food and Drug Administration approval for adults with the most common form of the bleeding disorder.